iRhythm Holdings, Inc. is a commercial-stage digital healthcare company that focuses on the advancement of cardiac care through its ambulatory electrocardiogram (ECG) monitoring products and services. The company's core business model revolves around the Zio service, an integrated ambulatory monitoring solution that combines wearable biosensor devices with cloud-based data analytics and artificial intelligence algorithms.
The company generates nearly all of its revenue from the Zio service in the United States, with international markets currently representing a small portion of its geographic footprint. The Zio product line includes the Zio XT, designed for long-term continuous monitoring for up to 14 days, and the Zio AT, which provides mobile cardiac telemetry by transmitting data wirelessly during the wear period to detect critical arrhythmias in near real-time.
iRhythm's competitive position is supported by its large database of curated heart rhythm data, which continuously trains its AI algorithms. This deep learning model can detect arrhythmias with high accuracy, improving diagnostic yields compared to traditional 24-to-48-hour Holter monitors. By offering a small, wire-free patch that facilitates patient compliance and an automated summary report for physicians, iRhythm holds a significant market share in the remote cardiac monitoring space. The company primarily serves cardiologists, electrophysiologists, and primary care physicians, aiming to reduce the overall cost of care by preventing downstream medical events such as strokes through early detection.
